Weight loss and treatment patterns in a real‐world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study)

Abstract

AbstractAimTo assess weight loss associated with liraglutide 3.0 mg treatment in individuals with obesity (body mass index [BMI] ≥30 kg/m2) or overweight (BMI > 27 to <30 kg/m2) in a reimbursed, real‐world setting in Switzerland.Materials and MethodsADDRESS was a non‐comparative, multicentre, retrospective exposure cohort study in Switzerland, examining weight loss in individuals with obesity or overweight whose treatment was reimbursed (divided into BMI subgroups) or non‐reimbursed. The primary outcomes were proportions of participants in the reimbursed cohort achieving predefined weight loss targets with liraglutide 3.0 mg at Week 16 (≥5% and ≥7% for the lower BMI [28 to <35 kg/m2 with weight‐related comorbidities] and higher BMI [≥35 kg/m2] subgroups, respectively) and Month 10 (additional ≥5% from Week 16; per Swiss reimbursement criteria).ResultsThe full analysis set comprised 258 individuals (195 reimbursed; 63 non‐reimbursed). In the reimbursed cohort, 139 individuals (71.3%) achieved their weight loss targets at Week 16. Of individuals who met the Week‐16 criteria, 43.2% attained an additional 5% weight loss at Month 10. In 162 individuals for whom data were recorded at Month 10, the mean (standard deviation) relative weight loss from baseline to Month 10 was −12.4% (6.4%).ConclusionsAlthough reimbursement criteria may be difficult to achieve, particularly the additional weight loss of 5% from Week 16 to Month 10, a clinically relevant overall weight loss from baseline to Month 10 was shown in most individuals with obesity or overweight who received liraglutide 3.0 mg.